|
?:abstract
|
-
At present, there are no effective treatments for coronavirus disease 2019 (COVID-19) and the therapeutic interventions are limited to supportive care, varying from symptomatic management to critical care support Corticoids are administered to reduce host inflammatory responses in the lungs The potential harm and the lack of proven benefit of corticosteroids cautions against their routine administration in COVID-19 patients outside the Randomized Clinical Trials (RCTs), with an exception of a concomitant indication, such as a refractory shock The amplified immune response and Cytokine Release Syndrome (CRS) are known to cause significant organ damage (lungs), providing a rationale for the use of monoclonal Antibody (mAb) Hyperimmune Immunoglobulins (Igs) from the recovered patients may also assist with improving the immune response and virus clearance Human Normal Immunoglobulins (HNIGs) can be administered in the early seven to ten days of infection, during peak viremia or in the absence of a primary immune response Ultimately, a vaccine could provide a potential permanent strategy, creating protective immunity for people and preventing future outbreaks ©Copyright (c) 2020
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}